Adipotide

Last Updated: August 2026

Adipotide is a synthetic peptidomimetic targeting PROHIBITIN on the vasculature of white adipose tissue, designed to induce apoptosis of fat-supplying blood vessels and consequent fat cell death. It is one of the earliest "vascular-targeting" approaches to obesity research. Development as a human therapeutic was halted due to nephrotoxicity signals in preclinical and early human work, but the compound remains a reference point in obesity research. Adipotide is not approved for any medical indication and is sold as a research-use-only material.

What is Adipotide and how does the vascular-targeting mechanism work?

Adipotide is a peptidomimetic consisting of a peptide that binds PROHIBITIN — a marker overexpressed on the vasculature of white adipose tissue — linked to a pro-apoptotic peptide (KLAKLAK)2 that induces mitochondrial disruption and apoptosis specifically in the targeted endothelium. By killing the blood vessels supplying white adipose tissue, Adipotide produces fat tissue regression via vascular starvation rather than appetite suppression or metabolic modulation. Evidence level: Preclinical (rodent, non-human primate); one Phase 1 human trial (prostate-cancer patients), no published results.

What does the research show for Adipotide?

In preclinical rodent and rhesus-monkey studies, adipotide induced targeted apoptosis in the blood vessels supplying white adipose tissue, producing substantial fat loss — up to about 11% body-weight reduction in obese monkeys over 4 weeks.1 source Separately, a single Phase 1 human trial was conducted — a dose-escalation study in obese men with castrate-resistant prostate cancer at MD Anderson Cancer Center (dosing began 2012; Arrowhead developed the drug). No efficacy or safety results from that trial have been published, and adipotide's obesity development program was subsequently discontinued.1 source development for obesity. The renal signal was attributed to off-target peptide accumulation in kidney tissue. Evidence level: Preclinical (rodent + non-human primate); one Phase 1 human trial (cancer patients), no efficacy results published; obesity development discontinued.

How does Adipotide compare to GLP-1-class weight-loss peptides?

Adipotide's mechanism (vascular-targeted adipocyte apoptosis) is fundamentally different from GLP-1 agonism (appetite suppression and metabolic modulation) — Adipotide kills fat tissue physically, GLP-1 agonists reduce caloric intake. GLP-1 compounds have advanced to Phase 3 and FDA approval; Adipotide's clinical development for obesity was halted due to safety concerns. The compounds are not therapeutically comparable.

What are the documented side effects of Adipotide?

Adipotide's principal safety concern is renal. In obese monkeys it caused predictable, dose-dependent and reversible changes in renal proximal tubule function, consistent with its pro-apoptotic (KLAKLAK)2 moiety accumulating in kidney tissue.1 source No human safety data have been published to characterize this effect in people; the renal liability documented in the animal studies is the reason usually given for discontinuing obesity development. This safety finding halted further development of Adipotide for non-life-threatening indications including obesity. Animal studies showed transient renal effects but the human signal was the development-stopping factor. Evidence level: renal safety signal documented in primate studies; no published human safety data.

What is the regulatory status of Adipotide?

Adipotide is not approved for any medical indication anywhere in the world as of August 2026. Clinical development for obesity was halted due to the renal safety signal in the Phase 1 trial. The compound remains available as research-use-only material from third-party laboratories. Buyers should be aware that Adipotide's development was discontinued specifically due to toxicity concerns — not due to lack of efficacy. Regulatory context in are peptides legal regulatory status by country.

Why does Adipotide vendor verification matter — and why is research-use particularly risky?

Adipotide carries a documented renal toxicity signal from human trials that halted clinical development for obesity, making research-use protocols substantially riskier than for compounds whose safety signals are less established. Independent HPLC purity testing and mass spectrometry identity confirmation are essential but they don't address the underlying toxicity risk. Buyers considering Adipotide should be aware that the compound was specifically discontinued for human use due to safety, not abandoned for efficacy. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Adipotide vendors?

Peptigrity collects independent third-party Certificates of Analysis for Adipotide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Given adipotide's documented renal liability, identity and purity confirmation matters — see what is on file on the independent Adipotide lab tests page.

Frequently Asked Questions

Why was Adipotide's obesity development halted?

Adipotide's dose-limiting toxicity is renal. In obese-monkey studies it caused reversible changes in kidney (renal proximal tubule) function, and its pro-apoptotic peptide accumulates in kidney tissue. That safety liability — not a positive efficacy readout — is the reason usually given for not advancing adipotide into larger obesity trials; a Phase 1 study in prostate-cancer patients ran but published no results.1 source The decision reflected the unfavorable risk-benefit profile for a non-life-threatening indication.

Is Adipotide effective for fat loss?

Preclinical rodent and rhesus-monkey studies showed substantial fat-mass reduction, but no human efficacy has been published. The one Phase 1 trial (in prostate-cancer patients) reported no efficacy results, and no obesity-specific human trial was completed — adipotide's fat-loss efficacy in humans is unestablished. for that indication.

Is Adipotide legal to purchase?

Adipotide is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption and carries documented renal toxicity signals from human trials. Country breakdown in peptide legal status guide.

How can I verify an Adipotide vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Note that purity verification confirms what's in the vial — it does not address Adipotide's underlying toxicity risk profile. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend an Adipotide dose?

No. Adipotide is not approved for human consumption, carries documented human-trial renal toxicity signals, and Peptigrity is an independent review platform, not a medical authority. Anyone considering Adipotide should be aware that clinical development for non-cancer indications was halted specifically for safety reasons. Consult a licensed physician.

Are there safer alternatives to Adipotide for fat loss research?

Peptigrity does not make medical recommendations, but FDA-approved alternatives for weight management exist — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are FDA-approved through prescription and have established safety profiles. The investigational retatrutide is in late-stage development. These are not direct mechanism analogs to Adipotide but are evidence-based options for the weight-loss research question.

This section is for educational and informational purposes only and does not constitute medical advice. Adipotide is not approved by the FDA or any other regulator for human use and carries documented renal toxicity signals that halted its clinical development for obesity. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.